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Abstract
Background: Improved insight into the molecular characteristics of the different ovarian cancer subgroups is
needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a)
identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovarian carcinoma
(CCC) and ovarian surface epithelium (OSE), b) evaluate selected miRNAs for association with clinical parameters
including survival and c) map miRNA-mRNA interactions.
Methods: Differences in miRNA expression between HGSC, CCC and OSE were analyzed by global miRNA
expression profiling (Affymetrix GeneChip miRNA 2.0 Arrays, n = 12, 9 and 9, respectively), validated by RT-qPCR
(n = 35, 19 and 9, respectively), and evaluated for associations with clinical parameters. For HGSC, differentially
expressed miRNAs were linked to differentially expressed mRNAs identified previously.
Results: Differentially expressed miRNAs (n = 78) between HGSC, CCC and OSE were identified (FDR < 0.01%), of
which 18 were validated (p < 0.01) using RT-qPCR in an extended cohort. Compared with OSE, miR-205-5p was the
most overexpressed miRNA in HGSC. miR-200 family members and miR-182-5p were the most overexpressed in
HGSC and CCC compared with OSE, whereas miR-383 was the most underexpressed. miR-205-5p and miR-200
members target epithelial-mesenchymal transition (EMT) regulators, apparently being important in tumor progression.
miR-509-3-5p, miR-509-5p, miR-509-3p and miR-510 were among the strongest differentiators between HGSC and CCC,
all being significantly overexpressed in CCC compared with HGSC. High miR-200c-3p expression was associated with
poor progression-free (p = 0.031) and overall (p = 0.026) survival in HGSC patients. Interacting miRNA and mRNA targets,
including those of a TP53-related pathway presented previously, were identified in HGSC.
Conclusions: Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a
carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in
both subgroups, among which miR-200c-3p was associated with survival in HGSC patients. A set of miRNAs differentiates
CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between
miRNAs and mRNAs in HGSC were mapped.
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Background
Ovarian cancer is the fourth and fifth most frequent
cause of cancer death in women in Norway and the U.S.,
respectively [1,2]. Two-thirds of patients have advanced-
stage disease (International Federation of Gynecology
and Obstetrics [FIGO] stage III-IV) at diagnosis, result-
ing in 5-year survival at <30% [1,2].
Ovarian carcinoma (OC) constitutes about 90% of
ovarian cancers, and is a heterogeneous group of tu-
mors, encompassing several distinct subgroups with re-
spect to molecular profiles, biological behavior and
clinical features [3-6]. Nevertheless, OC patients gener-
ally receive similar, non-individualized treatment. There-
fore, improved insight into the molecular characteristics
of the different OC subgroups may aid in development
of a more subgroup-specific treatment, thereby improv-
ing prognosis.
microRNAs (miRNAs) are short, non-coding RNA mol-
ecules, which by targeting mRNAs cause mRNA degrad-
ation or translational repression [7]. Since a single miRNA
may have multiple different mRNA targets and conversely,
a given mRNA might be targeted by multiple miRNAs,
miRNAs play a central role in regulating gene expression.
Alterations in miRNA expression level may consequently
alter the level of a wide spectrum of mRNAs and subse-
quently cellular functions.
miRNAs show abnormal expression patterns in different
cancer forms [8]. Some act as tumor suppressor genes or
oncogenes and may therefore be important in cancer de-
velopment [9,10]. Various gene expression analysis ap-
proaches, including microarrays, have identified aberrantly
expressed miRNAs in OC [9,11-26], of which some are re-
lated to progression [13], outcome [18-24] and chemo-
therapy resistance [23-25]. However, the studies have in
general utilized non-subgroup specific tumors [11], and
only a few included normal ovarian surface epithelium
(OSE) [15-17], which has been shown to be valid control
material [27,28].
The aim of this study was to identify miRNAs differen-
tially expressed between moderately and poorly differenti-
ated serous OC, referred to as high-grade serous OC
(HGSC), clear cell OC (CCC) and scrapings from OSE,
and to evaluate their association with clinical parameters,
including survival. To identify potential key molecular
pathways of the carcinogenesis of HGSC, differentially
expressed miRNAs and mRNAs identified previously [29]
were linked. We have identified several miRNAs differen-
tially expressed between HGSC, CCC and OSE, including
miR-200c-3p with apparent clinical relevance in HGSC.
Several interactions of potential oncogenic function be-
tween aberrantly expressed miRNAs and mRNAs in
HGSC have also been mapped, including interactions be-
tween miR-200 members and the epithelial-mesenchymal
transition (EMT) regulators ZEB1 and ZEB2.
Methods
Ethics statement
The study was approved by the Regional Committee of
Medical and Health Research Ethics of South-Eastern
Norway (ref.no.530-02163 and S-04300) and all partici-
pants signed informed consent.
Patients and material
Women were enrolled prior to operations for gynecological
diseases at Oslo University Hospital (OUH) during 2003–
2012. Patient information was obtained from hospital re-
cords and preoperative interviews. Patients were evaluated
routinely [29] and follow-up data, including clinical exami-
nations, laboratory analyses and imaging were available for
all patients. CA125 level was used as marker for therapy re-
sponse. CA125 normalization (<35 kU/L) was defined as op-
timal when achieved within four cycles of chemotherapy.
Time until progression and time until death were defined as
the time interval from the date of surgery to the date of first
confirmed disease recurrence and to the date of death, re-
spectively. Disease progression was based on CA125 level
increase according to GCIG (Gynecologic Cancer Inter-
group) criteria (www.gcig.igcs.org) and verified clinical re-
lapse, and the date of first event was used. Clinical data were
current as of March 20, 2013.
Tumors comprised primary OC obtained pre-chemo-
therapy. OSE samples were collected from patients with
benign diseases, as previously described [27]. Tumors
were snap-frozen in liquid nitrogen immediately after har-
vesting, whereas OSE samples were transferred to QiaZol
solution (Invitrogen, Carlsbad, CA). All samples were
stored at −80°C until processed.
The histological classification and clinical staging were
according to the World Health Organization classifica-
tion and FIGO, respectively. Tumors were reviewed by a
gynecological pathologist (BD) to confirm the histo-
logical type and grade. A frozen section from all biopsies
was examined prior to RNA isolation to ensure a tumor
component of at least 50% and absence of necrosis.
RNA preparation
Frozen tumors (<50 mg) were homogenized directly for
3 minutes in 700 μl QIAzol using a TissueLyzer (Qiagen,
Hilden, Germany). Total RNA was extracted using the
miRNeasy Mini Kit (Qiagen) and Phase Lock Gel™
Heavy (5 PRIME GmbH, Hamburg, Germany). RNA was
quantified with a NanoDrop® ND-1000 Spectrophotom-
eter (Saveen Werner, Malmö, Sweden), and quality
assessed on Agilent 2100 Bioanalyzer RNA 6000 Nano
Kits (Agilent Technologies, Palo Alto, CA). All samples
showed adequate RNA quantity and quality.
Global miRNA expression profiling
Global miRNA expression was analyzed in 12 HGSC, 9
CCC and 9 OSE samples. Total RNA (400 ng) was used
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for biotin labeling of miRNA by the Genisphere FlashTag
HSR kit following the manufacturer’s recommendations
(Genisphere, Hatfield, PA). Labeled miRNAs were hy-
bridized to the GeneChip miRNA 2.0 Array (Affymetrix,
Santa Clara, CA), representing 1,105 mature human
miRNAs, as recommended by the manufacturer. Arrays
were washed and stained using the FS-450 fluidics sta-
tion (Affymetrix). Signal intensities were detected by
Hewlett Packard Gene Array Scanner 3000 7G (Hewlett
Packard, Palo Alto, CA). Microarray data were deposited
in NCBI’s Gene Expression Omnibus (GEO) [30] and
are accessible through GEO Series accession number
GSE47841 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE47841).
Quantitative reverse transcription-polymerase chain
reaction (RT-qPCR)
Selected candidate miRNAs were validated by RT-qPCR
in all samples analyzed by global miRNA expression pro-
filing (except one excluded) and in additional samples,
totaling 35 HGSC, 19 CCC and 9 OSE samples. Custom-
made TaqMan® Low Density Array (TLDA) cards for hu-
man miRNA expression analysis (Applied Biosystems, Life
Technologies, Carlsbad, CA) were used for quantification
of specific miRNAs, each card allowing 384 simultaneous
qPCR reactions of 24 different miRNAs run in duplicates.
Included were two selected reference genes and one
mandatory control (U6 (mammu6) snRNA).
Total RNA (350 ng) was applied for reverse transcrip-
tion (RT) with stem-looped RT primer-mix, enabling
synthesis of cDNA from mature miRNAs. Unbiased
custom-based pre amplification was performed accord-
ing to protocols, using gene-specific forward and reverse
primers. The PCR reactions were performed on Unocy-
cler (VWR International, B-3001 Leuven, Belgium). The
TLDA cards were used for further PCR-amplification on
a ViiA7™ Real Time PCR system thermocycler and ana-
lyzed with ViiA7 RUO Software (Applied Biosystems,
Life Technologies).
Relative gene expression levels were calculated using
the comparative crossing threshold method of relative
quantification (ΔΔCq method) [31,32], and presented as
relative quantification cycle (ΔCq) and fold change (FC)
values. ΔCq was designated as the mean Cq (mean of
duplicates) of a miRNA in a sample subtracted by the
mean Cq (mean of duplicates) of two reference genes in
the same sample. Based on recommendations from the
manufacturer and comparison between the microarray
and RT-qPCR analyses, Cq expression cutoff was set to
30, which was applied for calculations. For analyzing as-
sociations with clinical parameters, ΔΔCq was calculated
as mean ΔCq of the OSE controls subtracted by ΔCq of
each tumor sample. For comparison of mean expression
levels between different groups, ΔΔCq was calculated as
mean ΔCq of one group subtracted by mean ΔCq of an-
other group (ΔCqOSE - ΔCqHGSC; ΔCqOSE - ΔCqCCC;
ΔCqHGSC - ΔCqCCC). FC was designated as 2
ΔΔCq.
All miRNAs analyzed were from Homo sapiens (hsa)
and the prefix hsa was therefore excluded.
Ingenuity pathway analysis (IPA)
Data were analyzed through the use of IPA (Ingenuity®
Systems, www.ingenuity.com), which was used for iden-
tifying biological functions and related diseases and for
mapping mRNA-miRNA interactions.
Statistical analysis
For computational analysis of the microarray data,
scanned images were processed using the AGCC (Affyme-
trix GeneChip Command Console) software, and the CEL
files were imported into Partek Genomics Suite software
(PGS; Partek, Inc., St Louis, MO). The Robust Multichip
Analysis (RMA) algorithm was applied for generation of
relative signal values and normalization. For expression
comparisons of different groups, a 1-way ANOVA model
followed by calculation of FDR was used. Results were
expressed as FC and p-values. Signal values were subjected
to a non-supervised cluster analysis using the Euclidean/
average linkage algorithm.
Associations between signal values and progression-free
survival (PFS) and overall survival (OS) were evaluated by
Cox regression analyses followed by FDR correction. FDR
q-values of 0.1 and 0.25 were used as significance levels
for PFS and OS, respectively.
When comparing ΔCq values in different histological
subgroups, a two-sided independent samples t-test was
used since the ΔCq values were close-to-normally distrib-
uted. Associations between FC values of the RT-qPCR
analyses and clinical parameters were evaluated. In order
to decide whether expression of a miRNA was significantly
associated with PFS and OS, Cox regression analyses were
used. When significant, Kaplan-Meier plots were used to
estimate survival curves for tertiles of the expression vari-
able. To compare miRNA expression levels in two groups
of patients, a two-sided Mann–Whitney U-test was used,
since the FC expression levels were not normally distrib-
uted. The results for each group are presented as medians.
A significance level of 1% was used for differential
miRNA expression, and 5% when analyzing associations
with clinical parameters. Statistical analyses were performed
using the SPSS-PC package (Version 20, Chicago IL).
Results
Patient characteristics
Clinicopathologic data for the RT-qPCR cohort are
shown in Table 1. All HGSC patients were diagnosed
with FIGO stage IIIc/IV, whereas CCC patients were di-
agnosed at all stages due to limited patient material. The
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patients had no disease other than OC influencing sur-
vival, were Caucasian, and except for 1 with HGSC and 2
with CCC all were in good preoperative condition [27].
Primary surgery was performed in all patients. With the
exception of 4 HGSC and 5 CCC patients, all received
platinum-based chemotherapy. The 4 HGSC patients were
considered to be in too poor general condition to tolerate
chemotherapy. Among CCC patients, 1 received paclitaxel-
based treatment, 1 was in too poor general condition, and 3
did not receive chemotherapy due to FIGO stage IA.
Global miRNA expression analyses
Seventy-eight miRNAs were differentially expressed be-
tween HGSC, CCC and OSE applying a FDR <0.01%.
Complete p- and FC values are available in Additional file
1. Principal component analysis showed that these miR-
NAs could distinguish the 3 groups almost perfectly
(Figure 1). Cluster analysis, visualized by a heatmap
(Figure 2) showed almost perfect segregation of the 3 groups.
Striking differences were observed between HGSC and OSE
samples, whereas CCC had an intermediate profile. More-
over, miR-508-5p, miR-509-3p, miR-509-5p, miR-509-3-5p,
miR-510 and miR-514b-5p clearly distinguished HGSC from
CCC. OSE control samples were homogeneous.
Evaluation of associations between global miRNA
expression and survival
Associations between miRNAs with signal values >7
(n = 297) and PFS (FDR q < 0.1) and OS (FDR q < 0.25)
were separately evaluated in HGSC and CCC. No statis-
tically significant associations were found. However,
when not corrected for multiple testing, 11 miRNAs had
p < 0.05, indicating an association with survival. Of these,
miR-505-5p, miR-1281 and miR-29b-2-5p had the lowest
p-values (p < 0.03), all with potential association with
survival in HGSC. These miRNAs were among the miR-
NAs chosen for RT-qPCR validation and subsequent
evaluation for association with outcome in the extended
patient cohort. Noteworthy, only miR-29b-2-5p was
among the differentially expressed miRNAs shown in
Figure 2.
RT-qPCR validation of selected miRNAs
Twenty-one miRNAs and 2 reference genes were se-
lected for RT-qPCR validation in the extended patient
material. Of these, 18 miRNAs (Table 2) were predomin-
antly selected based on differential expression (Figure 2).
All miRNAs with FC > ±20 (n = 16) and 2 of the mRNAs
with FC > ±15 were included, reaching a highest FC
Table 1 Clinicopathological and laboratory information for patients selected for RT-qPCR analysis
Parameter HGSCa, n = 35 CCCa, n = 19
Age; mean ± SD (range) 64.0 ± 11.3 (45–87) 63.9 ± 15.3 (28–83)
Preoperative CA125 (kU/L); mean ± SD 3023 ± 4129 1438 ± 2198
FIGO stage I 0 10
II 0 3
III 25 5
IV 10 1
Residual disease 0 cm 3 13
<2 cm 9 4
>2 cm 23 2
Start of chemotherapy (days after surgery); mean ± SD 27.7 ± 11.6 25.7 ± 13.8
CA125 responseb Yes 31 15
No 1 0
Optimal CA125 normalizationb Yes 20 13
No 14 3
Median time (months) until progression (95% CI) 10 (7–13) NAc
Median time (months) until death (95% CI) 26 (18–34) 105 (35–175)
Status at last follow-upd NED 1 11
AWD 1 1
DOD 33 6
DOUC 0 1
aHGSC: High-grade serous ovarian carcinoma; CCC: Clear cell ovarian carcinoma.
bAccording to the GCIG criteria (www.gcig.igcs.org). For HGSC: Two patients who received no postoperative treatment due to poor general condition, one patient
with preoperative CA125 < 70; For CCC: One patient who received no postoperative treatment due to poor condition, three patients with preoperative CA125 < 70.
cCould not be calculated since the Kaplan-Meier survival curve stays above 50%.
dNED = No evidence of disease; AWD = Alive with disease; DOD = Dead of disease; DOUC = Dead of unrelated cause.
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value of 105. Additionally, the 3 above-mentioned miR-
NAs were selected based on possible association with
survival. miR-24 and miR-26a were selected as reference
genes, having the lowest expression variation (0.11 and
0.10, respectively) in the global miRNA analysis. Their
mean value reduced the variation to 0.029, and their
mean Cq value was therefore used for calculations.
All miRNAs selected based on differential expression
were verified as markedly differentially expressed, with
p-values varying from 10-7 to 10-21 and FC values up to
95 (Table 3). When comparing HGSC with OSE, 7 and 6
miRNAs were over- and under-expressed in HGSC, re-
spectively. According to FC values, miR-205-5p was the
most overexpressed (FC = 74), followed by miR-200c-3p,
miR-182-5p, miR-141-3p and miR-200b-3p. When com-
paring CCC with OSE, 11 and 2 miRNAs were over-
and underexpressed, respectively, including 8 common
with the HGSC vs. OSE analysis. miR-182-5p best distin-
guished CCC from OSE (FC = 66), followed by miR-
200a-3p, miR-200c-3p, miR-200a-5p and 200b-3p. All
these miRNAs were overexpressed, whereas miR-383
was the most underexpressed in both HGSC and CCC.
Twelve miRNAs distinguished CCC from HGSC, all
except 1 being overexpressed in CCC. The miRNA with
highest FC values was miR-509-3-5p (FC = 95), followed
by miR-509-5p, miR-509-3p, miR-510 and miR-508-5p.
Experimental information annotated from IPA for
these specific miRNAs is provided in Table 4. As shown,
these miRNAs are active regulators of the expression of
several cancer-related mRNAs, including ZEB1, ZEB2,
VIM, VEGFA, NTRK3 and SPDEF, and most of the miR-
NAs are cancer-related. The table also highlights differ-
entially expressed miRNAs (Tables 2 and 3) and mRNAs
(FC > ±1.5) identified previously [29] in HGSC vs. OSE,
Figure 1 Principal component analysis (PCA). A two-dimensional PCA of 78 miRNAs found to be differentially expressed following ANOVA and
application of FDR < 0.01% based on global miRNA expression analyses in 12 high-grade serous ovarian carcinomas (HGSC; blue), 9 clear cell
ovarian carcinomas (CCC; red) and 9 ovarian surface epithelium (OSE; green).
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among others ZEB1, ZEB2 and VIM, interacting in-
versely with miR-200c-3p, miR-200a-3p, miR-205-5p
and miR-141-3p. Complete HGSC vs. OSE FC values for
the mRNAs listed in Table 4 are provided in Additional
file 2.
Associations between validated miRNA expression and
clinical parameters
All miRNAs validated by RT-qPCR were evaluated for as-
sociation with PFS, OS, optimal CA125 normalization and
residual disease (RD) in patients included in the RT-qPCR
analyses. In HGSC, miR-200c-3p was found to be associ-
ated with PFS (p = 0.031) and OS (p = 0.026). The miR-
200c-3p FC expression level was divided into tertiles, and
Kaplan-Meier plots made (Figure 3). Patients with highest
tertile level had shorter OS than patients with intermediate
or lowest levels, with median time until death of 18 and
30 months, respectively (Figure 3A). Patients with the high-
est tertile level had shorter PFS compared with patients
with lowest levels, with median time until progression of 7
and 11 months, respectively (Figure 3B). No association
was found between the miRNAs and CA 125 normalization
or RD (cut-off at 2 cm) in HGSC. The 3 miRNAs selected
for RT-qPCR based on possible association with survival
were not found to be associated with outcome.
In CCC, no associations with PFS or OS were found.
However, patients with macroscopic RD (cut-off at
0 cm) had significantly lower miR-202-3p (p = 0.018)
and miR-1281 (p = 0.035) levels (n = 6; median FC = −5.3
and −2.0, respectively) than patients without RD (n = 13;
median FC = 1.6 and −1.2, respectively). Associations
with CA 125 normalization could not be evaluated in
CCC, since all but 3 patients achieved optimal CA 125
normalization.
Figure 2 Cluster analysis heatmap. Cluster analysis heatmap of expression levels (signal values) of 78 miRNAs found to be differentially
expressed following ANOVA and application of FDR < 0.01% based on global miRNA expression analyses in 12 high-grade serous ovarian carcinomas
(HGSC; blue), 9 clear cell ovarian carcinomas (CCC; red) and 9 ovarian surface epithelium (OSE; green). Each column represents a miRNA and each row
a sample. The more over- and under-expressed the miRNA, the brighter the red and blue color, respectively.
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Table 2 Differentially expressed miRNAs between HGSC, CCC and OSE of global miRNA expression profiling* selected
for RT-qPCR validation
HGSC vs. OSEa CCC vs. OSEa CCC vs. HGSCa
miRNAs p-values FC values p-value FC value p-value FC value
miR-134 8.3 × 10-8 −16.7b 1.0 × 10-4 5.8
miR-141-3p 1.1 × 10-11 46.1 2.4 × 10-10 34.9
miR-182-5p 6.0 × 10-9 30.2 1.4 × 10-8 32.7
miR-200a-3p 7.3 × 10-10 33.6 1.3 × 10-9 38.8
miR-200a-5p 3.0 × 10-13 33.5 6.9 × 10-12 26.5
miR-200b-3p 1.1 × 10-9 29.1 2.9 × 10-8 21.1
miR-200c-3p 1.2 × 10-12 16.5 1.2 × 10-11 15.0
miR-202-3p 8.0 × 10-6 −36.9 2.3 × 10-4 16.3
miR-205-5p 4.9 × 10-5 105.1 3.1 × 10-3 −23.1
miR-383 8.2 × 10-12 −33.7 1.5 × 10-11 −38.7
miR-424-5p 2.6 × 10-9 −26.0 4.0 × 10-6 −10.1
miR-508-5p 4.4 × 10-3 11.6 3.1 × 10-6 75.0
miR-509-3p 4.3 × 10-3 −10.3 2.6 × 10-6 83.4
miR-509-5p 5.6 × 10-4 11.4 1.8 × 10-6 34.0
miR-509-3-5p 3.9 × 10-3 −10.2 1.9 × 10-6 84.6
miR-510 9.3 × 10-3 −5.2 7.9 × 10-3 6.1 3.0 × 10-6 31.7
miR-513a-5p 4.8 × 10-3 7.4 4.1 × 10-6 33.5
miR-514b-5p 9.7 × 10-3 −6.5 3.8 × 10-3 9.8 1.3 × 10-6 63.6
*Affymetrix GeneChip miRNA 2.0 Arrays. aHGSC: High-grade serous ovarian carcinoma. OSE: ovarian surface epithelium. CCC: Clear cell ovarian carcinoma.
b‘-’ illustrates underexpression. FC: Fold change. P-values are calculated on original data (before FDR corrections).
Table 3 Differentially expressed miRNAs (p < 0.01) between HGSC, CCC and OSE verified by RT-qPCR
HGSC vs. OSEa CCC vs. OSEa CCC vs. HGSCa
miRNAs p-values FC values p-values FC values p-values FC values
miR-134 8.7 × 10-11 −5.7b 3.1 × 10-6 4.3
miR-141-3p 1.7 × 10-18 40.3 7.2 × 10-11 45.3
miR-182-5p 9.5 × 10-15 42.4 1.2 × 10-8 66.2
miR-200a-3p 3.6 × 10-5 33.0 9.3 × 10-10 57.8
miR-200a-5p 3.1 × 10-15 33.8 4.3 × 10-11 53.0
miR-200b-3p 5.3 × 10-18 38.8 3.7 × 10-11 51.0
miR-200c-3p 6.0 × 10-21 48.2 3.2 × 10-12 53.4
miR-202-3p 1.3 × 10-14 −14.7 1.6 × 10-7 10.1
miR-205-5p 9.0 × 10-9 74.3 4.4 × 10-3 −8.4
miR-383 2.2 × 10-14 −36.6 9.8 × 10-10 −15.1 2.2 × 10-3 2.4
miR-424-5p 3.1 × 10-13 −10.7 3.5 × 10-4 −4.2 1.6 × 10-3 2.5
miR-508-5p 3.5 × 10-3 10.1 1.0 × 10-8 27.5
miR-509-3p 2.0 × 10-7 46.3
miR-509-5p 5.0 × 10-3 −4.1 2.4 × 10-3 13.3 1.3 × 10-8 54.7
miR-509-3-5p 1.1 × 10-4 −11.0 2.2 × 10-8 95.3
miR-510 2.5 × 10-3 9.0 8.7 × 10-10 32.9
miR-513a-5p 6.6 × 10-4 6.2 9.1 × 10-7 8.3
miR-514b-5p 9.7 × 10-5 12.1 2.3 × 10-9 25.8
aHGSC: High-grade serous ovarian carcinoma. OSE: ovarian surface epithelium. CCC: Clear cell ovarian carcinoma. b‘-’ illustrates underexpression. FC: Fold change.
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Ingenuity pathway analysis (IPA)
To identify miRNA-mRNA interactions in HGSC, dif-
ferentially expressed miRNAs in HGSC vs. OSE were
linked to differentially expressed mRNAs in HGSC vs.
OSE identified previously [29]. miRNAs and mRNAs of
the microarray analyses (ANOVA, FDR < 5%) were im-
ported to the IPA software and filtered for interactions.
When including miRNAs and mRNAs with FC ≥ ±10,
interactions of inverse miRNA-mRNA expression pai-
ring (55.4% of the interactions), interactions experi-
mentally observed and of high predicted confidence, 19
miRNAs targeting 47 mRNAs (Table 5) were found. All
but 3 miRNAs are included in Figure 2. Core analysis
was performed, and selected cancer-related functions are
shown in Table 5. Fifty-four RNAs were cancer-related,
of which 11 mRNAs and 8 miRNAs were OC-related
(italics). Thirty-one and 10 molecules were related to cell
proliferation and cell cycle, respectively. For a detailed
evaluation of the quality of the predicted miRNA-mRNA
interactions of Table 5, a plot showing the Context +
score as well as number of conserved binding sites
of these interactions (TargetScan) is given in Additional
file 3.
We previously presented a HGSC pathway comprising
VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all signifi-
cantly overexpressed in HGSC vs. OSE and directly
interacting with TP53 [29]. Through IPA, these mRNAs
were linked to differentially expressed miRNAs in HGSC
vs. OSE of the microarray analysis (ANOVA, FDR < 5%,
FC > ±2). When inverse and similar miRNA-mRNA ex-
pression pairing and all confidence levels were included,
26 miRNAs and 30 interactions were found (Figure 4).
Of these, 7 and 12 were experimentally observed and of
high predicted confidence, respectively. Among the miR-
NAs, 16 were under- and 10 overexpressed. All but 9
miRNAs are included in Figure 2.
Discussion
In this study, a number of miRNAs distinguishing HGSC
and CCC from OSE, as well as CCC from HGSC have
been identified, including a set validated by RT-qPCR.
Table 4 IPA based experimentally observed information for differentially expressed miRNAs and differential
expression (FC > ±1.5) of their regulated mRNA targets in HGSC
miRNAs mRNA targets Cancer
association
OC
association
miR-134↓ x
miR-141-3p↑ TGFB2↓, ZEB2↓, JAG1, BAP1, CLOCK, ELMO2, ERBB2IP, KLHL20,
MAP2K4, PLCG1, PTPRD, WDR37
x x (EC)
miR-182-5p↑ FOXO3, ADCY6, CASP2↑, CLDN17, NCAM1↓, NFASC↓, RARG, BCL2L14↑,
CARD11↑, CASP10↑, CASP12, CDH1↑, CDH4, CDK6, CLDN15↓, COL11A2,
COL4A4↓, FNDC3A↓, FOXO1↓, GADD45G↓, GJA3, IGF1R↓, INHBC, ITGA4,
LRP6, MALAT1↓, MITF↓, MTSS1, NLGN2, PGF, PIK3CA↑, RPS6KB1, SOS1, VWF↑
x x (EC)
miR-200a-3p↑ CTNNB1, VIM↓, ZEB1↓, ZEB2↓, BAP1, CDK6, CDKN1B↓, CTBP2, CYP1B1↑,
ELMO2, ERBB2IP, KLHL20, PLCG1, PTPRD↓, TUBB↑, WDR37, ZFPM2↓
x x (EC, ROC)
miR-200a-5p↑ x
miR-200b-3p↑ VIM↓, ZEB1↓, ZEB2↓, BAP1, ELMO2, ERBB2IP, ERRFI1, KLHL20, PLCG1,
PTPRD↓, RERE, WASF3, WDR37, ZFPM2↓
x x (ROC)
miR-200c-3p↑ CDH1↑, PTPN13↓, ZEB1↓, ZEB2↓, FHOD1, PPM1F, JAG1, MARCKS, VIM↓,
CDKN1B↓, ERRFI1↓, PLCG1
x x (EC)
miR-202-3p↓
miR-205-5p↑ ERBB3↑, F Actin, INPPL1↑, MED1, VEGFA↑, ZEB1↓, ZEB2↓, PRKCE x x (EC)
miR-383↓
miR-424-5p↓ FGFR1, MAP2K1, NFIA↓, PLAG1 x
miR-508-5p
miR-509-3p↓ NTRK3
miR-509-5p↓
miR-509-3-5p↓
miR-510↓ HTR3E, SPDEF↑ x
miR-513a-5p CD274 x
miR-514b-5p↓
IPA: Ingenuity Pathway Analysis. HGSC: High-grade serous ovarian carcinoma. OC: Ovarian carcinoma. EC: Endometrioid OC. ROC: Recurrent OC. Over- and underex-
pressed miRNAs (based on Tables 2 and 3) and mRNAs (based on global gene expression analysis [29]) in HGSC vs. ovarian surface epithelium (OSE) are indicated
by upward and downward arrows, respectively. A complete list of HGSC vs. OSE FC values for the mRNA targets is available in Additional file 2.
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These miRNAs could be involved in the biology of these
OC subgroups.
The most differentially expressed miRNAs in both
HGSC and CCC compared with OSE were miR-200
family members, including miR-200a-3p, miR-200b-3p,
miR-200c-3p and miR-141-3p. These miRNAs are aber-
rantly expressed in different cancers [33-36], and have
been found to be overexpressed in serous and clear cell
OC, although few CCC were analyzed [17,22,26].
miR-200 family members have been demonstrated to
regulate EMT by targeting ZEB1 and ZEB2, resulting in
altered expression of the cell-cell adhesion molecule E-
cadherin [37-40]. E-cadherin down-regulation is appar-
ently important in cancer progression, facilitating cell
detachment and metastasis. At a favorable distant loca-
tion, cells may undergo mesenchymal-epithelial transi-
tion (MET) and re-express E-cadherin. This is supported
by the finding of elevated E-cadherin and reduced ZEB1
in metastatic epithelial ovarian cancer [41], as well as by
our findings of overexpressed miR-200 family members
and underexpression of ZEB1 and ZEB2 in metastatic
HGSC. ZEB1 and ZEB2 are also targets of miR-205-5p
[37], which was highly overexpressed in HGSC com-
pared with OSE and CCC.
miR-200c-3p and miR-200b-3p, having similar seed se-
quences, have been shown to decrease VIM expression
and thereby its protein vimentin [39]. Vimentin is found
in various non-epithelial cells, especially mesenchymal
cells, and is used as marker for EMT during metastasis.
Elevated expression of miR-200c-3p and miR-200b-3p,
resulting in reduced vimentin levels, is therefore ex-
pected in metastatic cancer, where epithelial features are
important for re-colonization, in concordance with our
findings.
Interestingly, among the IPA documented mRNA tar-
gets of the differentially expressed miRNAs in this study,
ZEB1 and ZEB2 were among the most underexpressed
mRNAs in HGSC compared with OSE. Even though the
miRNA-mRNA interactions are not verified in the HGSC
material presented, the inverse expression of miR-200
members and ZEB1, ZEB2 and VIM, as well as of miR-
205-5p and ZEB1 and ZEB2, support a probable inter-
action also in HGSC.
miR-182-5p had the highest FC in CCC compared with
OSE. This miRNA regulates the expression of PIK3CA, a
frequently mutated gene in CCC and a candidate for tar-
geted therapy [42]. Little is known about miR-200a-5p, al-
though it has been related to colorectal cancer [36].
To the best of our knowledge, the present study is the
first to identify differentially expressed miRNAs in a
relatively large CCC series. The miRNAs most clearly
separating CCC from HGSC were miR-509-3-5p and
miR-509-5p, having similar seed sequences, as well as
miR-509-3p and miR-510. miR-509-3p has been shown to
target NTRK3 [43], encoding the receptor tyrosine ki-
nase TrkC, which is involved in the oncogenic PIK3CA
Figure 3 Kaplan-Meier survival curves for miR-200c-3p expression in HGSC patients. Overall survival (OS) curves (A) and progression-free
survival (PFS) curves (B) according to miR-200c-3p expression level (FC) tertiles in patients with high-grade serous ovarian carcinomas (HGSC,
n = 35) based on significant association between miR-200c-3p and PFS (p = 0.031) and OS (p = 0.026). A: High expression. B: Intermediate
expression. C: Low expression. The symbol “+” indicates censoring. Median time until progression and death is given in Table 1.
Vilming Elgaaen et al. BMC Cancer 2014, 14:80 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/80
pathway. miR-509-3p, miR-509-3-5p and also miR-513a-
5p have been found overexpressed in stage I OC [23], and
miR-509-5p have been found to inhibit cancer cell pro-
liferation [44]. miR-510 targets SPDEF [45], which have
been found underexpressed in OC compared with breast
carcinoma [46]. Our findings of an underexpressed miR-
510 and overexpression of SPDEF in HGSC support an
interaction also in this cancer subgroup.
In spite of the relatively small sample size, high level
of miR-200c-3p was found to be associated with short
PFS and OS in HGSC, indicating it may be a prognostic
marker for HGSC. This finding is in accordance with a
study analyzing miRNA expression in SC vs. normal
ovaries [22]. The fact that most of its differentially
expressed and experimentally observed mRNA targets
were found underexpressed may bolster the conclusion
that miR-200c-3p is associated with survival. This
miRNA has also been associated with survival in stage I
OC patients [47] and chemotherapy response [48]. miR-
200c-3p was among the most differentially expressed
miRNAs in both HGSC and CCC compared with OSE
separately, and had the lowest p-value in both compari-
sons. miR-200c-3p has previously been found to be over-
expressed in SC [22,26], HGSC cell lines [49], serum
from HGSC patients [49] and in a small series of CCC
[26]. Based on the relatively small number of HGSC pa-
tients, the findings of the survival analysis should be
verified in an extended material, and negative findings
should be interpreted with caution.
A larger cohort is warranted for CCC to explore the
associations between miRNAs and survival. However,
miR-202-3p and miR-1281 were found to be associated
with RD in CCC, although this could not be adjusted for
stage due to the small series.
We further mapped IPA based interactions between
differentially expressed mRNAs and miRNAs in HGSC.
Unfortunately, global mRNA expression analysis of CCC
was not available. The vast majority of these interacting
RNAs has previously been associated with cancer and
cancer-related functions, and may represent important
key molecular pathways in HGSC. Moreover, differen-
tially expressed miRNAs in HGSC were linked to over-
expressed mRNAs in a molecular pathway for HGSC. In
this latter IPA analysis, both over- and underexpressed
miRNAs were included. The functional association be-
tween an overexpressed miRNA and overexpressed
miRNA targets, if any, may be indirect or be due to
compensatory mechanisms. For example, VEGFA, which
we previously found to be overexpressed and associated
with PFS in HGSC [29], is a target of miR-200c-3p. A
possible explanation for interaction, in spite of both be-
ing overexpressed, may be due to adaptive mechanisms
leading to overexpression of miR-200c-3p, in an attempt
to reduce VEGFA and consequently carcinogenesis.
However, an interaction resulting in activation of VEGFA
expression can not be ruled out [50-52]. The identified in-
teractions are IPA based, and should be experimentally
evaluated in HGSC.
OSE was in this study used as control material, since
OC is presumed to originate in the OSE [53]. However,
Table 5 Interacting miRNAs and mRNAs in HGSC -
differentially* and inversely expressed
miRNAs and mRNA targets FC values
miR-1341,5 −16.7
KLHL141, PAX81,3,5 9.6 – 29.3
miR-141-3p1,2,6/ miR-200a-3p1,2,6 46.1
FOXP21,2,5, HLF1, PCDH95, PEG31,6, SCN7A1, SDC21,2,3,4,5,6 −9.6 – -24.7
miR-182-5p1,2 30.2
ANGPTL11,2,5, CACNB21,5, FOXP21,2,5, KCNMB21,5,
PID11, SDC21,2,3,4,5,6, TMEM150C
−9.6 – -14.6
miR-183-5p1,2,6 11.7
ABCA81, HLF1 −11.6 – -17.8
miR-187-3p1 12.8
TSPAN51,2 −11.3
miR-200b-3p1,2,6/ miR-200c-3p1,2,6 29.1
CACNB21,5,CDH111,2,5,6, COL4A31,2,5,6, GPM6A1,
HLF1, HS3ST3A11, LEPR1,2,4,5,6, MCC1,2, NEGR11,2,6, SDC21,2,3,4,5,6
−9.6 – -21.6
miR-202-3p −36.9
RRM21,2,4,6 16.9
miR-203-3p1,2,6 13.6
ANGPTL11,2,5, EDNRA1,2,6, FOXP21,2,5,GNG42,6,
IGFBP51,2,3,4,5,6, NEGR11,2,6, SMAD91
−9.7 – -15.0
miR-205-5p1,6 105.1
BAMBI1,2,5,6, NR3C21,2,5,6, PEG31,6 −10.1 – -24.7
miR-376c-3p1 −11.7
EHF1,2,3,6, LRP81,5,6 11.9 – 12.6
miR-379-5p −10.3
KLHL141 29.3
miR-381-3p1 −12.6
EGFL61, NOTCH31,2,3,5,6, RRM21,2,4,6 9.7 – 16.9
miR-383 −33.7
MAL2 32.8
miR-424-5p1,2,3,4,5,6 −26.0
AHNAK21, CCNE11,2,3,4,6, ESRP11,6, HMGA11,2,3,4,6,
LAMP31,2, PSAT11, UCP22,5, VAMP81,2
9.9 – 24.0
miR-485-5p1 −13.6
KRT71,3,4, LRP81,5,6, ST141 10.5 – 16.2
miR-887 −9.6
TMEM139 11.7
miR-4324 −12.5
ERBB31,2,3,5,6, GALNT6 17.9 – 23.7
HGSC: High-grade serous ovarian carcinoma. *ANOVA, FDR < 5%, FC ≥ ±10 in
HGSC vs. ovarian surface epithelium. All interactions are of high predicted
confidence, whereas the interactions between miR-424-5p and CCNE1, HMGA1,
PSAT1 and UCP2 are experimentally observed. 1, 2, 3, 4, 5, 6Related to cancer
(italicized for ovarian cancer), cellular growth and proliferation, cell cycle, DNA
replication, recombination and repair, cell-to-cell signaling and interaction,
cellular development, respectively. Results were generated through the use of
Ingenuity Pathway Analysis.
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an alternative origin of a subset of OC has recently been
proposed, suggesting implanted epithelial cells of the fal-
lopian tube and endometrium in the ovary as an origin
for HGSC and CCC, respectively [3]. The basis for this
proposed model are findings of tubal dysplasia and tubal
intraepithelial carcinoma (TIC) in women predisposed
to [54,55] or operated for [56] HGSC, as well as a mo-
lecular resemblance of TIC to HGSC [57-59]. However,
since a direct transition from lesions in the Fallopian
tube to OC has still not been demonstrated, OSE may
still be the origin for OC. Interestingly, a common em-
bryological origin of fimbrial epithelium and OSE has
been hypothesized [60], which may explain a similar pre-
disposition for the development of tubal and ovarian
cancer.
Conclusions
Several miRNAs significantly differentially expressed be-
tween HGSC, CCC and OSE were identified through glo-
bal miRNA expression profiling and RT-qPCR validation
analysis, suggesting a role for these miRNAs in OC. The
differences emphasize the biological distinctiveness of
these OC subgroups. Highly overexpressed miRNAs in-
cluding miR-205-5p in HGSC and members of the miR-
200 family in HGSC and CCC target EMT drivers, and
may be important in OC progression. Overexpression of
miR-182-5p and miR-200a-5p and underexpression of
miR-383 was also found in HGSC and CCC. Some miR-
NAs separating CCC from HGSC were also identified,
including miR-509-3-5p, miR-509-5p, miR-509-3p and
miR-510. miR-200c-3p, the most significantly differentially
expressed miRNA in both HGSC and CCC, was found to
be associated with PFS and OS in HGSC, representing a
potential prognostic marker for HGSC. In HGSC, several
interacting differentially expressed miRNAs and mRNAs
were mapped, but need to be experimentally verified. The
identified miRNAs should be explored in future studies as
candidate biomarkers and therapeutic targets.
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